$16.88
+0.44(2.68%)
Mkt Cap $527M
$13.79
$30.85
52-Week Range
At A Glance
1
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
2
Revenue is primarily driven by Laboratory Services (100%) and Therapeutic Development (0%).
3
Most recently: Results of Operations and Financial Condition. On February 27, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing its financial resu (2026-02-27).
$527M
Market Cap
$327M
Revenue
-$61M
Net Income
Employees1,313
Fundamentals
How The Business Makes Money
Revenue by Segment
Laboratory Services100%($2.9B)
Therapeutic Development0%($1M)
Revenue by Geography
US85.4%($825M)
Non Us7.3%($71M)
CN3.8%($37M)
Other Countries3.5%($34M)
Activity
Analyst View
Company Profile
CIK0001674930
ISINUS3596641098
CUSIP359664109
Phone626 350 0537
Address4978 Santa Anita Avenue, El Monte, CA, 91780, US
SEC EDGAR